KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBT: 2009-2025

Historic EBT for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's EBT rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • As of Q3 2025, Arbutus Biopharma's EBT stood at -$7.7 million, which was down 408.95% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's EBT peaked at $2.5 million during Q2 2025, and registered a low of -$24.5 million during Q1 2025.
  • In the last 3 years, Arbutus Biopharma's EBT had a median value of -$17.9 million in 2024 and averaged -$15.7 million.
  • Its EBT has fluctuated over the past 5 years, first slumped by 44.32% in 2023, then spiked by 112.64% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's EBT stood at -$21.3 million in 2021, then declined by 2.87% to -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then spiked by 35.28% to -$12.5 million in 2024, then surged by 60.81% to -$7.7 million in 2025.
  • Its EBT stands at -$7.7 million for Q3 2025, versus $2.5 million for Q2 2025 and -$24.5 million for Q1 2025.